ABCAM Plc ABC AGM Statement

  ABCAM Plc (ABC) - AGM Statement

RNS Number : 2213P
ABCAM Plc
22 October 2012




For                                                                  immediate 
release
22 October 2012

                                      

                                      

                                  ABCAM PLC

                          ("Abcam" or the "Company")

                                      

                                Result of AGM

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of  protein 
research tools,announces  that  all resolutions  put  to its  Annual  General 
Meeting held earlier today were duly passed.

At  the  meeting,  Michael  Redmond,  Abcam's  Chairman,  thanked  Prof   Tony 
Kouzarides, a co-founder of  the Company and a  Non-Executive Director for  14 
years, who, as previously announced, stepped down from the Board at the  close 
of the Annual General Meeting.

Michael Redmond,  Abcam's Chairman,  said: "I  would like  to thank  Tony,  on 
behalf of everyone at Abcam, for the immense contribution he has made, playing
a vital role in the Company's success. We wish him well for the future."



For further information please contact:

Abcam                                                 + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer

Jeff Iliffe, Chief Financial Officer

www.abcam.com
Numis Securities - Nominated Advisor and Joint Broker + 44 (0) 20 7260 1000
Michael Meade / Nick Westlake - Nominated Advisor

James Black - Corporate Broking
Peel Hunt LLP - Joint Broker                          + 44 (0) 207 418 8900
Andy Crossley - Corporate Broking
Buchanan                                              + 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles





Notes for editors



About Abcam plc



Abcam is a producer  and distributor of high  quality protein research  tools. 
These tools enable life  scientists to analyse components  of living cells  at 
the molecular level, which is essential in understanding health and disease.

Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK),
Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan),
Hangzhou and Hong Kong (both in China), allowing it to serve a global customer
base in over  130 countries.  Abcam employs over  600 staff  across its  eight 
operating companies.

Abcam now has an  online catalogue of more  than 98,000 products sourced  from 
more than 400 suppliers. The catalogue includes a growing range of non-primary
antibody  products   such  as   secondaries,  proteins,   peptides,   lysates, 
immunoassays and other kits. Products are available for life science  research 
and distributed to academic and commercial users. A highly developed eCommerce
platform, which  includes  regional  websites for  the  Chinese  and  Japanese 
markets, allows customers to access up-to-date and detailed technical  product 
data sheets at the Company's website, www.abcam.com.

Abcam was admitted to AIM in November 2005 and trades under the ticker  symbol 
ABC. The Company's vision is to  be the world's leading life science  reagents 
company.



                     This information is provided by RNS
           The company news service from the London Stock Exchange

END


AGMBKBDQBBDDBKB -0- Oct/22/2012 12:52 GMT
 
Press spacebar to pause and continue. Press esc to stop.